公开(公告)号：US12115414B1

公开(公告)日：2024-10-15

申请号：US17985358

申请日：2022-11-11

申请人： Thomas C. Chuang

发明人： Thomas C. Chuang

IPC分类号： A63B24/00 ,  A61B5/00 ,  A61B5/11 ,  A63B1/00 ,  A63B69/00 ,  A63B71/06 ,  G01N33/574 ,  G01P3/00 ,  G01P13/00 ,  G01S19/19 ,  G01S19/52 ,  G06F18/21 ,  G06T7/00 ,  G06T7/12 ,  G06V20/69 ,  G06V40/20 ,  G09B19/00 ,  G16H50/30 ,  G06T7/11

CPC分类号： A63B24/0006 ,  A61B5/112 ,  A61B5/681 ,  A63B1/00 ,  A63B24/0003 ,  A63B24/0021 ,  A63B69/0028 ,  A63B71/0619 ,  G01N33/57415 ,  G01P3/00 ,  G01P13/00 ,  G01S19/19 ,  G01S19/52 ,  G06F18/2193 ,  G06T7/0012 ,  G06T7/12 ,  G06V20/698 ,  G06V40/23 ,  G09B19/00 ,  G09B19/0038 ,  G16H50/30 ,  A61B5/0002 ,  A61B5/1112 ,  A61B2560/0242 ,  A63B24/00 ,  A63B2220/12 ,  A63B2220/16 ,  A63B2220/20 ,  A63B2220/22 ,  A63B2220/40 ,  A63B2220/833 ,  A63B2220/836 ,  A63B2230/06 ,  A63C2203/18 ,  G01N2800/52 ,  G01N2800/54 ,  G06T7/11 ,  G06T2207/10056 ,  G06T2207/30024

摘要： Methods and apparatuses for athletic performance and technique monitoring are disclosed. In one example, a sensor output is received associated with a movement of a user torso during a running motion. The sensor output is analyzed to identify an undesirable torso motion.

公开(公告)号：US20240295568A1

公开(公告)日：2024-09-05

申请号：US18599665

申请日：2024-03-08

申请人： LABORATORY CORPORATION OF AMERICA HOLDINGS ,  UAB RESEARCH FOUNDATION

发明人： Kerri FORD ,  Jeffrey R. CURTIS

IPC分类号： G01N33/68 ,  G16H10/40 ,  G16H50/20

CPC分类号： G01N33/6893 ,  G16H10/40 ,  G16H50/20 ,  G01N2333/4737 ,  G01N2333/575 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/60

摘要： Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.

公开(公告)号：US20240288432A1

公开(公告)日：2024-08-29

申请号：US18572370

申请日：2022-06-21

申请人： AROCELL AB

发明人： Staffan ERIKSSON ,  Per VENGE

IPC分类号： G01N33/574 ,  C07K16/40

CPC分类号： G01N33/57426 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/565 ,  G01N2333/9122 ,  G01N2800/54

摘要： The invention relates to predicting cancer relapse or predicting patient survival by determining a level of serum thymidine kinase 1 (STK1) material in a body sample from a patient diagnosed with hematological cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1. The determined level of STK1 material is compared with a threshold value selected based on an age of the patient. Cancer relapse is then predicted based on the comparison.

公开(公告)号：US20230280346A1

公开(公告)日：2023-09-07

申请号：US18171569

申请日：2023-02-20

申请人： IMMUNIS.AI, INC.

发明人： Amin I. Kassis ,  Harry Stylli ,  Colleen Kelly ,  Geoffrey Erickson ,  Kirk J. Wojno

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  G01N2800/52 ,  C12Q2600/158 ,  G01N2500/00 ,  G01N2333/90 ,  G01N2333/7158 ,  G01N2333/46 ,  C12Q2600/106 ,  C12Q2600/118 ,  G01N2500/04 ,  G01N2800/50 ,  G01N2800/54

摘要： The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer

公开(公告)号：US11651863B2

公开(公告)日：2023-05-16

申请号：US16271827

申请日：2019-02-09

申请人： AstraZeneca Computational Pathology GmbH

发明人： Guenter Schmidt

IPC分类号： G16H50/30 ,  G16B25/10 ,  G16B45/00 ,  G16B20/00 ,  G16B40/00 ,  G16H40/63 ,  G01N33/574 ,  G16H30/40 ,  G16H50/20 ,  G16B40/20 ,  C12Q1/6886

CPC分类号： G16H50/30 ,  C12Q1/6886 ,  G01N33/57434 ,  G16B20/00 ,  G16B25/10 ,  G16B40/00 ,  G16B40/20 ,  G16B45/00 ,  G16H30/40 ,  G16H40/63 ,  G16H50/20 ,  G01N2570/00 ,  G01N2800/342 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/7028

摘要： A method that provides a graphical indication of whether a patient will have cancer recurrence uses univariate and bivariate prognostic features that were generated as part of a minimal spanning tree (MST). The method determines the values of first and second features. A first value is measured by detecting objects in an image of tissue from the cancer patient stained with a protein-specific IHC biomarker. A second value is measured using objects marked with an mRNA-specific probe biomarker detected in the tissue. The first feature is the univariate prognostic feature for cancer recurrence in a cohort of cancer patients. A combination of the first and second features is the bivariate prognostic feature for cancer recurrence in the cohort. The first and second features are elements of the MST. Nodes of the MST represent the univariate features, edges represent the bivariate features, and edge weights represent prognostic significance of bivariate features.

公开(公告)号：US20190252075A1

公开(公告)日：2019-08-15

申请号：US16237392

申请日：2018-12-31

申请人： Definiens AG

发明人： Guenter Schmidt

IPC分类号： G16H50/30 ,  C12Q1/6886 ,  G16H50/20 ,  G16B40/20

CPC分类号： G16H50/30 ,  C12Q1/6886 ,  G01N33/57434 ,  G01N2570/00 ,  G01N2800/342 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/7028 ,  G16B20/00 ,  G16B25/10 ,  G16B40/00 ,  G16B40/20 ,  G16B45/00 ,  G16H30/40 ,  G16H40/63 ,  G16H50/20

摘要： An analysis and display system generates and displays a score indicative of whether cancer will recur in a patient. In a learning phase, a phenomic feature of tumor tissue is measured. A corresponding phenomic feature is defined. The phenomic feature may be measured through image analysis of digital images taken of tissue slices stained with IHC-based stains. A genomic feature of the tissue is also measured. This may entail obtaining a probe count indicative of a degree of expression of a particular gene. A bivariate feature is calculated using both the phenomic and genomic information. A network including the bivariate feature is displayed. In a diagnostic phase, raw phenomic and genomic data is obtained from a tissue sample taken from the patient. From the data, a score for the bivariate feature, and scores for the other features, are calculated. The score is a function of the underlying feature scores.

公开(公告)号：US20190252044A1

公开(公告)日：2019-08-15

申请号：US16271827

申请日：2019-02-09

申请人： Definiens AG

发明人： Guenter Schmidt

IPC分类号： G16B45/00 ,  G16B25/10

CPC分类号： G16H50/30 ,  C12Q1/6886 ,  G01N33/57434 ,  G01N2570/00 ,  G01N2800/342 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/7028 ,  G16B20/00 ,  G16B25/10 ,  G16B40/00 ,  G16B40/20 ,  G16B45/00 ,  G16H30/40 ,  G16H40/63 ,  G16H50/20

摘要： A method that provides a graphical indication of whether a patient will have cancer recurrence uses univariate and bivariate prognostic features that were generated as part of a minimal spanning tree (MST). The method determines the values of first and second features. A first value is measured by detecting objects in an image of tissue from the cancer patient stained with a protein-specific IHC biomarker. A second value is measured using objects marked with an mRNA-specific probe biomarker detected in the tissue. The first feature is the univariate prognostic feature for cancer recurrence in a cohort of cancer patients. A combination of the first and second features is the bivariate prognostic feature for cancer recurrence in the cohort. The first and second features are elements of the MST. Nodes of the MST represent the univariate features, edges represent the bivariate features, and edge weights represent prognostic significance of bivariate features.

公开(公告)号：US20190185582A1

公开(公告)日：2019-06-20

申请号：US16323224

申请日：2017-08-09

申请人： Alertix Veterinary Diagnostics AB

发明人： Staffan ERIKSSON ,  Henrik RÖNNBERG ,  Kiran Kumar JAGARLAMUDI

IPC分类号： C07K16/40 ,  C07K16/18 ,  G01N33/573 ,  G01N33/574 ,  G01N33/541 ,  G01N33/543

CPC分类号： C07K16/40 ,  C07K16/18 ,  C07K2317/20 ,  C07K2317/34 ,  G01N33/541 ,  G01N33/5434 ,  G01N33/573 ,  G01N33/574 ,  G01N2800/52 ,  G01N2800/54

摘要： A kit useful for determination of non-human mammal TK1 in a sample is disclosed. The kit comprises a first antibody immobilized to a support or intended to be immobilized to a support. The kit also comprises a second antibody. One of the antibodies has specificity for a peptide consisting of a first amino acid sequence from a C-terminal region of non-human mammal TK1 and the other antibody has specificity for a peptide consisting of an amino acid sequence from an active site of TK1 or for a peptide consisting of a second amino acid sequence from the C-terminal region.

公开(公告)号：US20180348221A1

公开(公告)日：2018-12-06

申请号：US15781373

申请日：2016-12-09

申请人： SANFORD HEALTH

发明人： Kristi A. EGLAND ,  Rick L. EVANS ,  James V. POTTALA

IPC分类号： G01N33/574

CPC分类号： G01N33/57415 ,  G01N2800/52 ,  G01N2800/54

摘要： Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRPIO, GFRA1, LGALS3, CST2, DKK1, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A 1 AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.

公开(公告)号：US10012654B2

公开(公告)日：2018-07-03

申请号：US14653750

申请日：2013-12-23

申请人： University of Tromsø

发明人： Jon Florholmen ,  Trine Olsen ,  Renathe Rismo ,  Rasmus Goll ,  Guanglin Cui

IPC分类号： C12Q1/68 ,  G01N33/00 ,  A61K39/00 ,  G01N33/566 ,  G01N33/68 ,  C12Q1/6883 ,  G06F19/00 ,  G01N33/50

CPC分类号： G01N33/6863 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5088 ,  G01N33/6893 ,  G01N2333/525 ,  G01N2333/54 ,  G01N2333/57 ,  G01N2800/065 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56 ,  G16H50/20

摘要： The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNFα therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNFα, IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR.